Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Moxifloxacin hydrochloride
88
CHF
CHF 88.00
In stock
CDX-M0189-M05050 mgCHF 88.00
| Product Details | |
|---|---|
| Synonyms | BAY 12-8039; Alelox; 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride |
| Product Type | Chemical |
| Properties | |
| Formula | C21H24FN3O4 . HCl |
| MW | 401.43 . 36.46 |
| CAS | 186826-86-8 |
| RTECS | VB1983750 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥97% (NMR) |
| Appearance | Light yellow powder. |
| Solubility | Soluble in DMSO (10mg/ml) or water (5mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | IDIIJJHBXUESQI-DFIJPDEKSA-N |
| Smiles | O=C1C(C(O)=O)=CN(C2CC2)C3=C(OC)C([NH+]4C[C@](NCCC5)([H])[C@]5([H])C4)=C(F)C=C31.[Cl-] |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Moxifloxacin is a fourth-generation synthetic broad-spectrum fluoroquinolone antibiotic. It is used against both Gram-positive and Gram-negative bacteria and to treat bacterial infections associated with bronchitis, sinusitis, and other conditions. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase (Topo II) and topoisomerase IV by binding to the enzyme-DNA complex. Compared to mammalian DNA gyrase, moxifloxacin has 100 times higher affinity for bacterial DNA gyrase. Can also be used as reference compound.
Product References
(1) M. Souli, et al.; Int. J. Antimicrob. Agents. 10, 23 (1998) | (2) C. Ballow, et al.; Clin. Ther. 21, 513 (1999) | (3) A. Dalhoff, et al.; Clin. Infect. Dis. 32, S22 (2001) | (4) R. Kishii, et al.; Antimicrob. Agents Chemother. 47, 77 (2003) | (5) M. Miravitlles; J. Chron. Obstruct. Pulmon. Dis. 2, 191 (2007) | (6) M. Miravitlles & A. Anzueto; Expert Opin. Pharmacother. 9, 1755 (2008) (Review) | (7) H. Takiff & E. Guerrero; Antimicrob. Agents Chemother. 55, 5421 (2011) | (8) M.M. Al Omari, et al.; Profiles Drug Subst. Excip. Relat. Methodol. 39, 299 (2014) (Review)